CBL、NRAS、KRAS、RUNX1 和 TP53 突变对原发性骨髓纤维化突变增强国际预后评分系统(MIPSS70/plus/plus v2.0)的预后贡献
该研究在 363 例原发性骨髓纤维化患者中评估 CBL、NRAS、KRAS、RUNX1 和 TP53 突变是否可增强 MIPSS70/plus/plus v2.0 的预后价值。中位随访 4.6 年,单变量分析显示 CBL、NRAS、KRAS、TP53 与生存相关,但多变量分析及 C 统计量均未证实这些突变可独立提升现有模型的预后效能。
要点
- 在 363 例原发性骨髓纤维化患者中,CBL、NRAS、KRAS、TP53 突变单变量与生存相关,RUNX1 突变未达统计学显著。
- 多变量分析未证实 CBL、NRAS、KRAS、TP53 或 RUNX1 突变具有独立预后贡献。
- 将上述突变纳入 HMR+ 类别未改善 MIPSS70/plus/plus v2.0 的模型效能(C 统计量)。
核心结论
- MIPSS70/plus/plus v2.0 及其遗传组分的预后完整性得以维持,纳入 CBL、NRAS、KRAS 和 RUNX1 等新近描述的 HMR 突变未显著提升其价值。
- 需进一步研究以阐明 TP53 突变及其等位基因状态 apparent 的额外预后价值。
研究设计与样本
- 研究纳入 363 例原发性骨髓纤维化患者,中位年龄 58 岁,60% 为男性。
- 评估 CBL、NRAS、KRAS、RUNX1 和 TP53 突变对 MIPSS70/plus/plus v2.0 预后系统的额外贡献。
主要发现
- 中位随访 4.6 年,记录 135 例(37%)死亡和 42 例(11.6%)白血病转化。
- 单变量分析显示 CBL(HR 2.8;p < .001)、NRAS(HR 2.4;p < .001)、KRAS(HR 2.1;p = .01)和 TP53(HR 2.4;p = .004)突变与生存显著相关,RUNX1 突变未达统计学显著(HR 1.8;p = .08)。
- 多变量分析证实 ASXL1(HR 1.8;p = .007)、SRSF2(HR 4.3;p < .001)、U2AF1Q157(HR 2.9;p = .004)和 EZH2(HR 2.4;p < .001)突变具有独立预后贡献,而 IDH1/2(p = .3)、TP53(p = .2)、CBL(p = .3)、NRAS(p = .8)和 KRAS(p = .2)突变未显示独立预后贡献。
- 在包含突变和核型的多变量分析、MIPSS70/plus/v2.0 复合评分与各新近描述 HMR 突变(除 TP53 外)的多变量分析、以及将 CBL、NRAS、KRAS 和 TP53 纳入 HMR 组分(HMR+ 类别)的改良 MIPSS70/plus/plus v2.0 分析中,均未显示这些突变的额外预后价值。
- HMR+ 增强的 MIPSS70/plus/plus v2.0 模型未改善模型效能(以 C 统计量衡量)。
关键数值与推荐
- MIPSS70/plus/plus v2.0 中已纳入的高分子风险(HMR)突变包括 ASXL1、SRSF2、EZH2、IDH1/2 和 U2AF1Q157。
- 本队列突变频率:JAK2 61%、CALR 24%、MPL 6%、ASXL1 29%、SRSF2 10%、U2AF1Q157 5%、EZH2 10%、IDH1/2 4%、TP53 5%、CBL 5%、NRAS 7%、KRAS 4%、RUNX1 4%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 需进一步研究以阐明 TP53 突变及其等位基因状态 apparent 的额外预后价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Contemporary risk models in primary myelofibrosis (PMF) include the mutation (MIPSS70) and mutation/karyotype enhanced (MIPSS70 plus/v2.0) international prognostic scoring systems. High molecular risk (HMR) mutations incorporated in one or both of these models include ASXL1, SRSF2, EZH2, IDH1/2, and U2AF1Q157; the current study examines additional prognostic contribution from more recently described HMR mutations, including CBL, NRAS, KRAS, RUNX1, and TP53. In a cohort of 363 informative cases (median age 58 years; 60% males), mutations included JAK2 61%, CALR 24%, MPL 6%, ASXL1 29%, SRSF2 10%, U2AF1Q157 5%, EZH2 10%, IDH1/2 4%, TP53 5%, CBL 5%, NRAS 7%, KRAS 4%, and RUNX1 4%. At a median follow-up of 4.6 years, 135 (37%) deaths and 42 (11.6%) leukemic transformations were recorded. Univariate analysis confirmed significant survival impact from the original MIPSS70/plus/v2.0 HMR mutations as well as CBL (HR 2.8; p < .001), NRAS (HR 2.4; p < .001), KRAS (HR 2.1; p = .01), and TP53 (HR 2.4; p = .004), but not RUNX1 mutations (HR 1.8; p = .08). Multivariate analysis (MVA) that included both the original and more recently described HMR mutations confirmed independent prognostic contribution from ASXL1 (HR 1.8; p = .007), SRSF2 (HR 4.3; p < .001), U2AF1Q157 (HR 2.9, p = .004), and EZH2 (HR 2.4; p < .001), but not from IDH1/2 (p = .3), TP53 (p = .2), CBL (p = .3), NRAS (p = .8) or KRAS (p = .2) mutations. The lack of additional prognostic value from CBL, NRAS, KRAS, RUNX1, and TP53 was further demonstrated in the setting of (i) MVA of mutations and karyotype, (ii) MVA of MIPSS70/plus/v2.0 composite scores and each one of the recently described HMR mutations, except TP53, and iii) modified MIPSS70/plus/plus v2.0 that included CBL, NRAS, KRAS, and TP53 as part of the HMR constituency, operationally referred to as "HMR+" category. Furthermore, "HMR+" enhancement of MIPSS70/plus/plus v2.0 did not result in improved model performance, as measured by C-statistics. We conclude that prognostic integrity of MIPSS70/plus/plus v2.0, as well as their genetic components, was sustained and their value not significantly upgraded by the inclusion of more recently described HMR mutations, including CBL, NRAS, KRAS, and RUNX1. Additional studies are needed to clarify the apparent additional prognostic value of TP53 mutation and its allelic state.
引用
- Loscocco GG, Rotunno G, Mannelli F, et al. The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis. Am J Hematol. 2023. PMID: 37846894. doi:10.1002/ajh.27136
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。